BERKELEY, CA, November 3, 2023 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today that it will present preclinical data of its lead asset, ACTM-838, in a poster presentation at the 2023 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, California. The presentation will feature data examining […]
Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.
Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.